Gilead Sciences Inc vs Johnson & Johnson
GILD vs JNJ — side-by-side comparison from reported financials. GILD leads 4, JNJ leads 7 of 11 comparable metrics.
Gilead Sciences Inc
GILD · Healthcare
$151.20+2.79%Mixed
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | GILD | JNJ |
|---|---|---|
| Price | $151.20 | $261.79 |
| Market cap | $187B | $631B |
| Revenue (TTM) | $30.5B | $97.9B |
| Revenue growth | +2.6% | +5.6% |
| Net margin | -10.6% | 21.5% |
| Free cash flow | $12.9B | $22.2B |
| Net cash (debt) | ($24.9B) | ($27.8B) |
| 1-year price return | +29.5% | +37.0% |
| P/E | 22.0 | 29.9 |
| P/E vs own history (cheap-side %) | 78% | 16% |
| Dividend yield | 3.24% | 2.00% |
| Return on equity | -16% | 26% |
| CV checks passed | 9 of 11 | 10 of 11 |
| Employees | 17,000 | 140,800 |
Full résumé-style profiles: GILD CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.